Similarly, Chau et al. (2006a,b), designed a dextran-peptide-methotrexate conjugate for tumor site specific release of chemotherapeutics in response to tumor-associated enzymes i.e., MMP-2 and MMP-9 via cleavage of peptide linkage. This evidence concerns the gene MMP9 and neoplasm.